Medtronic Grew 13.7%. An Extra Week Supplied Half of It

Medtronic reported first-quarter fiscal 2027 results before the US open on Tuesday 1 September 2026, and the number that led every write-up was 13.7% organic revenue growth on revenue of $9.76bn, roughly 200 basis points above the midpoint of its own guidance. Non-GAAP diluted earnings per share came in at $1.45 against a consensus of $1.39; GAAP diluted EPS was $1.14. The company raised full-year fiscal 2027 organic revenue growth guidance by 50 basis points to 7.25%–7.75% and lifted its non-GAAP EPS range to $5.94–$6.00. The shares gained about 5% from a prior close of $90.65, on a session in which the Dow fell more than 300 points.

Here is the part that explains the quarter properly, and it sits in Medtronic's own release rather than in the headlines. Fiscal 2027 is a 53-week year, and the extra selling week landed in the first quarter. Medtronic estimates it contributed approximately $570m, or about 670 basis points, to enterprise organic revenue growth. Strip it out and the underlying rate is around 7% — which is almost exactly the full-year guidance range the company just raised to. The 13.7% is real revenue, but it is not a run rate, and the market did not treat it as one.

What actually happened

Once the extra week is set aside, this was still Medtronic's strongest underlying quarter in close to eight years excluding the distorted COVID comparisons — which is the genuinely notable claim, and a much harder one to make than a 13.7% headline.

Cardiovascular was the engine, growing 18.9% organically. Within it, Cardiac Rhythm Management grew 15% and Cardiac Ablation Solutions grew 88%. Electrophysiology therapies as a whole rose 29% globally. That is one franchise, one technology transition, and it is carrying the group's acceleration almost single-handedly. Medtronic also announced an expanded CE Mark indication for its Affera Mapping and Ablation System and Sphere-9 catheter, covering ventricular arrhythmias — an extension of the same franchise into a new indication rather than a new leg of growth.

Alongside the results, Medtronic announced a $700m partnership with Cornerstone Robotics to expand access to its Sentire Surgical System in selected non-US markets. This is a capital-allocation decision worth reading carefully: Medtronic is buying distribution reach in surgical robotics through a partnership structure rather than building or owning it outright.

The guidance raise deserves to be sized honestly. Fifty basis points of organic growth and six cents of EPS at the midpoint is, in absolute terms, a small revision — the new EPS midpoint of $5.97 sits barely above the $5.95 consensus. On a company of Medtronic's scale, that is not what a 5% move is paying for.

Why the market reacted the way it did

If the raise is arithmetically trivial and the headline growth rate is inflated by a calendar quirk the company disclosed openly, why did the shares add roughly 5% on a down day for the index?

The answer is that the market was not repricing this quarter. It was repricing the question of whether Medtronic is still a 4%-growth company. For most of the past decade that was the fair characterisation: a very large, very diversified medical device group with excellent franchises, structurally low single-digit growth, and a valuation that reflected it. An underlying quarter near 7%, with the acceleration visible in a specific and identifiable franchise rather than spread thinly across everything, is evidence against that characterisation. A guidance range of 7.25%–7.75% for the full year says management believes it too.

The second element is quality of composition. Cardiac Ablation Solutions growing 88% is not price or currency or a restocking effect. It is share capture in a technology transition — pulsed field ablation displacing older radiofrequency and cryoablation approaches in atrial fibrillation. Markets pay more for growth they can attribute to a mechanism than for growth they cannot, and this is about as attributable as it gets.

The Cornerstone Robotics deal added a third strand. Surgical robotics has been the part of the Medtronic story where the gap between ambition and commercial traction has been widest, and a $700m commitment to expand non-US access reads as management choosing speed over ownership.

The Openbook read

Growth is the factor that moves, and it moves for the right reason — but not by as much as the headline implies. Anyone scoring growth off 13.7% is scoring a 14-week quarter against 13-week comparators. The defensible input is the ~7% underlying rate and the raised 7.25%–7.75% full-year guide. That is a genuine step up from Medtronic's historical trend and it is corroborated by the company's own forward guidance, which is the more reliable of the two signals. The concentration risk is explicit: strip out Cardiac Ablation Solutions and the group's growth rate is materially lower.

Momentum improves modestly. A 5% single-day move on results, against a falling index, is a positive signal, and it comes after a period in which Medtronic has generally been a market performer rather than a leader. But one session does not establish a trend, and momentum built on a single franchise's share gains is only as durable as that franchise's runway.

Profitability is stable rather than improving, and the label matters. The $1.45 figure is non-GAAP; GAAP diluted EPS was $1.14, and the roughly 31-cent gap is the usual amortisation and restructuring bridge that Medtronic has carried for years. It is not a red flag on its own — large acquisitive medtech groups all look like this — but it does mean that a Profitability score built on adjusted EPS is measuring management's preferred presentation. The underlying picture is a business with strong gross margins and a persistent gap between reported and adjusted earnings.

Solvency is the factor to keep an eye on rather than the one to celebrate. Medtronic carries substantial debt from a long history of large acquisitions, and it maintains a dividend it has raised for decades — a commitment that constrains flexibility. Committing $700m to a robotics partnership is affordable, but it is a reminder that the growth Medtronic is buying increasingly costs cash rather than arriving organically.

Reward/Risk comes down to one question: what happens to the group growth rate when the pulsed field ablation share-gain curve flattens? PFA went from essentially no presence in US atrial fibrillation catheter purchasing in early 2023 to the large majority of that spend by early 2026. A transition that fast is a transition that finishes fast. Once the technology has substantially replaced what came before, growth reverts from share capture to underlying procedure volume — a mid single-digit market. The reward case is that Medtronic sustains a high-single-digit group rate long enough for the multiple to re-rate. The risk case is that the market is extrapolating a share-gain curve with maybe two or three good years left in it, and that the Cardiovascular growth rate decelerates sharply from a very high base while nothing else in the portfolio is growing fast enough to take over.

The read-across

The clearest implication is for the rest of the electrophysiology field, and it is a warning as much as an endorsement. Boston Scientific effectively created the PFA market and held all of it as recently as 2023; by early 2026 its share of PFA spend had fallen to roughly 41% as Medtronic, Johnson & Johnson and Abbott entered. Medtronic's 88% growth in Cardiac Ablation Solutions is being taken from somewhere, and in a market this concentrated it is being taken from the incumbent.

The wider read for the sector is that the pool is still expanding fast enough that share loss and revenue growth can coexist — PFA moved from nothing to the dominant share of atrial fibrillation catheter spend in about three years. That is why Boston Scientific can lose share and still grow. The moment worth watching is when penetration matures and the market becomes zero-sum: that is when a 41% share and an 88% growth rate start describing the same fight rather than two separate good outcomes.

For medtech generally, Medtronic's quarter supports the view that procedure volumes remain healthy across cardiac, neuroscience and surgical categories. Investors comparing device names on growth and returns can screen the sector on our screener, though it is worth adjusting any cross-company growth comparison for Medtronic's extra fiscal week before drawing conclusions.

What to watch next

• The second-quarter print, due around late November. This is the first clean comparison — a normal 13-week quarter with no calendar benefit. If organic growth prints in the 7%–8% range, the acceleration thesis holds. If it prints nearer 5%, then the first quarter was mostly the extra week and a favourable comparator.
• Cardiac Ablation Solutions growth rate. Not whether it grows, but by how much less. The sequence of that deceleration from 88% is the single most informative number Medtronic will report over the next four quarters.
• Whether the full-year guide moves again. Management raised the organic range to 7.25%–7.75% one quarter into the year. A second raise would suggest genuine conservatism; leaving it unchanged after a 200 basis point beat would suggest the first quarter borrowed from the rest.
• Cornerstone Robotics execution. The $700m buys access in selected non-US markets. Watch for disclosed placements or procedure volumes for the Sentire system, which is where a partnership either becomes a business or stays a line item.
• Competitive PFA data and approvals. The expanded Affera CE Mark for ventricular arrhythmias opens a new indication; competing launches and label expansions from Boston Scientific, Johnson & Johnson and Abbott will determine how much of that runway Medtronic keeps.

Openbook tracks Medtronic alongside its device peers including Boston Scientific and Abbott Laboratories, with the five-factor scores refreshed as each reports.